| I-28 Asuka Suzuki A Bayesian approach for population pharmacokinetic modeling of alcohol in Japanese Subjects Wednesday 10:30-12:00 |
| I-31 Ana Novakovic A longitudinal model linking absolute lymphocyte count (ALC) and volume of T2 lesions to expanded disability status scale (EDSS) in patients with relapsing-remitting multiple sclerosis (RRMS) Wednesday 10:30-12:00 |
| I-46 Jonás Samuel Pérez-Blanco Population PK and exposure-response analysis of sleep parameters for JNJ-42847922, a novel Orexin 2 receptor antagonist Wednesday 10:30-12:00 |
| I-47 Carlos Perez-Ruixo Identifying lack of adherence to antipsychotic treatment using plasma concentrations measurements Wednesday 10:30-12:00 |
| I-55 Angelica Quartino Crenezumab exposure-response across Alzheimer’s Disease endpoints supports a higher dose for Phase 3 Wednesday 10:30-12:00 |
| I-64 Alberto Russu Dose-conversion factors for risperidone and paliperidone formulations based on steady-state PK similarity Wednesday 10:30-12:00 |
| II-08 Marina Senek Population pharmacokinetic model for levodopa/carbidopa microtablets in Parkinson’s disease patients and healthy subjects Wednesday 15:10-16:30 |
| II-43 Eline van Maanen A systems pharmacology approach unravels the dynamics of the APP pathway and unfolds Aß oligomer modulation Wednesday 15:10-16:30 |
| III-14 Francois Gaudreault Circadian quantitative system pharmacology model to inform clinical study design and translation to human Thursday 09:50-11:20 |
| III-24 Monia Guidi Adequacy of open-loop Target Controlled Infusion devices during anesthesia Thursday 09:50-11:20 |
| III-41 Jin Jin Crenezumab exposure-response across Alzheimer’s Disease endpoints supports a higher dose for Phase 3 Thursday 09:50-11:20 |
| III-44 Siv Jonsson Placebo and drug response assessment on Unified Parkinson’s Disease Rating Scale using longitudinal Item Response Modelling Thursday 09:50-11:20 |
| IV-07 Muhammad Waqar Ashraf A semi-mechanistic model to characterize the pharmacokinetics of orally administered S-Ketamine in healthy human subjects Thursday 14:45-16:15 |
| IV-21 Souvik Bhattacharya Longitudinal Parkinson’s Disease Progression Model using Item-Response-Theory Utilized to Predict Treatment Effect of Levodopa Thursday 14:45-16:15 |
| IV-52 Olivier David CNP520 Phase III dose selection support: Identifying the doses producing a desired reduction in CSF Aß-40 Thursday 14:45-16:15 |
